Ribavirin administration for chronic hepatitis C is associated with the development of haemolytic anaemia, which affects treatment efficacy and tolerability. In a pilot study, the exogenous administration of erythropoietin has been shown to be beneficial, reducing the rate of ribavirin dose reduction. How ribavirin administration affects normal erythropoietin production has not been determined.
Aim
To investigate the endogenous erythropoietin response in hepatitis C patients with ribavirin-induced anaemia.
Methods
Serum erythropoietin was measured before and during interferon–ribavirin treatment in 18 HCV-positive subjects. Mathematical analysis and modelling were applied to compare the degree of erythropoietin increase in HCV-positive and in otherwise healthy anaemic patients, and estimate the endogenous excess erythropoietin production in response to ribavirin-induced anaemia.
Results
Erythropoietin concentration increased significantly in response to anaemia caused by ribavirin. The physiological erythropoietin response to the ribavirin-induced anaemia was as adequate in HCV-positive subjects as it is in anaemic subjects without liver disease. The recommended exogenous erythropoietin dose appears three-times greater than the endogenous erythropoietin boost.
Conclusion
Chronic liver damage by HCV does not affect the physiological erythropoietin response to ribavirin-induced anaemia. While the rationale for erythropoietin treatment of ribavirin-induced anaemia is not straightforward, the currently recommended dosing regimen should be reassessed.
References
1.
EASL International Consensus Conference on Hepatitis C: Paris, 26–28 February 1999, Consensus Statement. Journal of Hepatology1999; 30: 956–961.
2.
BodenheimerH.C.Jr., LindsayK.L., DavisG.L., LewisJ.H., ThungS.N., & SeeffL.B.Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology1997; 26: 473–477.
3.
MaddreyW.C.Safety of combination interferon α-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Seminars in Liver Disease1999; 19(Suppl. 1): 67–75.
4.
GlueP.The clinical pharmacology of ribavirin. Seminars in Liver Disease1999; 19(Suppl. 1): 17–24.
5.
JarvisS.M., ThornJ.A., & GlueP.Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. British Journal of Pharmacology1998; 123: 1587–1592.
6.
LertoraJ.J., RegeA.B., LacourJ.T., FerenczN., GeorgeW.J., VanDykeR.B., AgrawalK.C., & HyslopN.E.Jr.. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clinical Pharmacology & Therapeutics1991; 50: 442–449.
7.
CanonicoP.G., KastelloM.D., SpearsC.T., BrownJ.R., JacksonE.A., & JenkinsD.E.Effects of ribavirin on red blood cells. Toxicology & Applied Pharmacology1984; 74: 155–162.
8.
CosgriffT.M., HodgsonL.A., CanonicoP.G., WhiteJ.D., KastelloM.D., DonovanJ.C., & RossP.E.Morphological alterations in blood and bone marrow of ribavirin-treated monkeys. Acta Haematologica1984; 72: 195–200.
9.
PageT., & ConnorJ.D.The metabolism of ribavirin in erythrocytes and nucleated cells. International Journal of Biochemistry1990; 22: 379–383.
10.
Fabianowska-MajewskaK., DuleyJ.A., & SimmondsH.A.Effects of novel anti-viral adenosine analogues on the activity of S-adenosylhomocysteine hydrolase from human liver. Biochemical Pharmacology1994; 48: 897–903.
11.
De FranceschiL., FattovichG., TurriniF., AyiK., BrugnaraC., ManzatoF., NoventaF., StanzialA.M., SoleroP., & CorrocherR.Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology2000; 31: 997–1004.
12.
ReichardO., NorkransG., FrydenA., BraconierJ.H., SonnerborgA., & WeilandO.Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet1998; 351: 83–87.
13.
McHutchisonJ.G., GordonS.C., SchiffE.R., ShiffmanM.L., LeeW.M., RustgiV.K., GoodmanZ.D., LingM.H., CortS., & AlbrechtJ.K.Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine1998; 339: 1485–1492.
14.
PoynardT., MarcellinP., LeeS., NiederauC., MinukG.S., IdeoG., BainV., HeathcoteJ., ZeuzemS., TrepoC., & AlbrechtJ.Randomised trial of interferon α-2b and ribavirin for 48 weeks or for 24 weeks versus interferon α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet1998; 352: 1426–1432.
15.
DavisG.L., Esteban-MurR., RustgiV., HoefsJ., GordonS.C., TrepoC., ShiffmanM.L., ZeuzemS., CraxiA., LingM.H., & AlbrechtJ.Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New England Journal of Medicine1998; 339: 1493–1499.
16.
ErslevA.J.Erythropoietin. New England Journal of Medicine1991; 324: 1339–1344.
17.
KouryM.J., & BondurantM.C.Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science1990; 248: 378–381.
18.
GabriloveJ.Overview: erythropoiesis, anemia, and the impact of erythropoietin. Seminars in Hematology2000; 37(Suppl. 6): 1–3.
19.
DonnellyS.Why is erythropoietin made in the kidney? The kidney functions as a critmeter. American Journal of Kidney Diseases2001; 38: 415–425.
20.
TongE.M., & NissensonA.R.Erythropoietin and anemia. Seminars in Nephrology2001; 21: 190–203.
21.
GoodnoughL.T., SkikneB., & BrugnaraC.Erythropoietin, iron, and erythropoiesis. Blood2000; 96: 823–833.
22.
TalalA.H., WeiszK., HauT., KreiswirthS., & DieterichD.T.A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-α. American Journal of Gastroenterology2001; 96: 2802–2804.
23.
WassermanR., BrauN., HassaneinT.I., BiniE., SulkowskiM., & DieterichD.T.Once weekly epoietin α increases hemoglobin and decreases ribavirin discontinuation among HCV patients who develop anemia on ribavirin/interferon treatment. Hepatology2000; 32(Suppl.): 368.
24.
DieterichD.T., WassermanR., BrauN., HassaneinT.I., BiniE.J., & SulkowskiM.Once-weekly recombinant human erythropoietin (Epoetin α) facilitates optimal ribavirin dosing in hepatitis C virus-infected patients receiving interferon-α2b/ribavirin combination therapy. Gastroenterology2001; 120(Suppl.): 340.
25.
WeiszK.B., BraunJ.F., DieterichD.T., HergenroederP.F., KreiswirthS.J., MullenM.P., McMeekingA.A., & TirelliR.Erythropoietin use for ribavirin/interferon-induced anemia in hepatitis C patients.38th International Congress on Antimicrobial Agents & Chemotherapy1998; 359.
26.
DesmetV.J., GerberM., HoofnagleJ.H., MannsM., & ScheuerP.J.Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology1994; 19: 1513–1520.
27.
BarosiG.Inadequate erythropoietin response to anemia – definition and clinical relevance. Annals of Hematology1994; 68: 215–223.
28.
BeguinY., ClemonsG.K., PootrakulP., & FilletG.Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood1993; 81: 1067–1076.
29.
ErslevA.J.The therapeutic role of recombinant erythropoietin in anemic patients with intact endogenous production of erythropoietin. Seminars in Oncology1992; 19(Suppl. 8): 14–18.
30.
MillerI., & FreundJ.E.Inferences concerning means. In: Probability and Statistics for Engineers, 3rd Edition. Edited by MillerI., & FreundJ.E.1985; pp. 185–228. Englewood Cliffs, NJ: Prentice-Hall Inc.
31.
RoqueM.E., SandovalM.J., & AggioM.C.Serum erythropoietin and its relation with soluble transferrin receptor in patients with different types of anaemia in a locally defined reference population. Clinical & Laboratory Haematology2001; 23: 291–295.
32.
EmburyS.H., GarciaJ.F., MohandasN., Pennathur-DasR., & ClarkM.R.Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia. New England Journal of Medicine1984; 311: 291–295.
33.
McMahonF.G., VargasR., RyanM., JainA.K., AbelsR.I., PerryB., & SmithI.L.Pharmacokinetics and effects of recombinant-human-erythropoietin after intravenous and subcutaneous injections in healthy-volunteers. Blood1990; 76: 1718–1722.
34.
McHutchisonJ.G., PoynardT., HarveyJ., GaraudJ.J., & AlbrechtJ.K.The effect of dose reduction on sustained response in patients with chronic hepatitis C receiving interferon α-2b in combination with ribavirin. Hepatology2000; 32(Suppl.): 247.
35.
MannsM.P., McHutchisonJ.G., GordonS.C., RustgiV.K., ShiffmanM., ReindollarR., GoodmanZ.D., KouryK., LingM., & AlbrechtJ.K.Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958–965.
36.
CrottyS., CameronC.E., & AndinoR.RNA virus error catastrophe: direct molecular test by using ribavirin. Proceedings of the National Academy of Sciences, USA2001; 98: 6895–6900.
DavisG.L., NelsonD.R., & ReyesG.R.Future options for the management of hepatitis C. Seminars in Liver Disease1999; 19(Suppl. 1): 103–112.
39.
KasperC.Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies. Annals of Hematology2001; 80: 319–329.
40.
JelkmannW.Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Current Pharmaceutical Biotechnology2000; 1: 11–31.
41.
EschbachJ.W., & AdamsonJ.W.Guidelines for recombinant human erythropoietin therapy. American Journal of Kidney Diseases1989; 14(Suppl. 1): 2–8.
42.
LuftF.C.Erythropoietin and arterial hypertension. Clinical Nephrology2000; 53(1 Suppl.): S61–64.
43.
SundalE., & KaeserU.Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrology Dialysis Transplantation1989; 4: 979–987.
44.
EschbachJ.W., AbdulhadiM.H., BrowneJ.K., DelanoB.G., DowningM.R., EgrieJ.C., EvansR.W., FriedmanE.A., GraberS.E., HaleyN.R.. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a Phase III multicenter clinical trial. Annals of Internal Medicine1989; 111: 992–1000.
45.
SowadeB., SowadeO., MocksJ., FrankeW., & WarnkeH.The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. International Journal of Molecular Medicine1998; 1: 303–314.
46.
EschbachJ.W., KellyM.R., HaleyN.R., AbelsR.I., & AdamsonJ.W.Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. New England Journal of Medicine1989; 321: 158–163.
47.
WinearlsC.G.Recombinant human erythropoietin: 10 years of clinical experience. Nephrology Dialysis Transplantation1998; 13(Suppl. 2): 3–8.
48.
GoodnoughL.T.The safety of recombinant human erythropoietin therapy in autologous blood donors. Journal of Laboratory & Clinical Medicine1994; 124: 17–18.
